1
Yale Cancer Center - Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 8
New Haven, CT 06511
1 of 2
- Yale Cancer Center - Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 8New Haven, CT 06511
- Smilow Cancer Hospital Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 2North Haven, CT 06473
Joseph Kim, MD
Medical Oncology, Hematology & Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Internal Medicine and Medical Oncology
Biography
Joseph Kim, MD, is an associate professor at Yale School of Medicine and the director of Prostate Cancer Research at Yale Cancer Center. A Yale Medicine oncology specialist, he delivers compassionate, patient-centered, and evidence-based care for patients with genitourinary cancer including prostate cancer, bladder cancer, testicular cancer, and penile cancer. Dr. Kim offers advanced treatments, such as cancer immunotherapy and oral inhibitors based on genomic biomarkers for prostate cancer and bladder cancer.
His research interests encompass developing novel anti-cancer therapies for genitourinary cancers through early phase clinical trials. Dr. Kim's research also explores changes in tumor DNA during treatment for patients with advanced prostate cancer.
Dr. Kim's impactful research has been recognized through several awards, including the Young Investigator Award and the Merit Award from the Conque Cancer Foundation with the American Society of Clinical Oncology, as well as the Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute.
Titles
- Associate Professor of Internal Medicine (Medical Oncology)
- Director, Prostate Cancer Research
- Lecture Coordinator in Hematology/Oncology, Yale Affiliated Hospital Program
Education & Training
- FellowNational Institutes of Health (2013)
- ResidentEmory University School of Medicine (2010)
- MDWake Forest University School of Medicine (2007)
- BACovenant College, Biology, Pre-Medicine (2001)
Languages Spoken
- English
- 한국어 (Korean)
Additional Information
Honors & Recognitions
- Cancer Clinical Investigator Team Leadership Award (CCITLA): NCI (2021)
- Young Investigator Award: Conquer Cancer Foundation, American Society of Clinical Oncology (2013)
- Merit Award: Conqer Cancer Foundation, American Society of Clinical Oncology (2013)
Professional Service
- ASCO-SEP (2021 - Present): Editor
- Frontiers Oncology (2019 - Present): Reviewer
- Current Oncology Reports (2015 - Present): Editor
- American Association for Cancer Research (2014 - Present): Member
- Society of Immunotherapy of Cancer (2013 - Present): Member
- American Society of Clinical Oncology (2010 - Present): Member
Publications
- Ünlü S, Shin J, Par-Young J, Simonov M, Vinetz J, Petrylak D, Kang I, Kim J. Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients. Cancer Investigation 2022, 41: 77-83. PMID: 36373994, DOI: 10.1080/07357907.2022.2139839.
- Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. Journal Of Clinical Oncology 2022, 41: 871-880. PMID: 36256912, PMCID: PMC9901975, DOI: 10.1200/jco.21.02947.
- Unlu S, Kim JW. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer. Current Oncology Reports 2022, 24: 1619-1631. PMID: 35931885, DOI: 10.1007/s11912-022-01305-0.
- Unlu S, Shin J, Par-Young J, Vinetz J, Petrylak D, Kang I, Kim J. Effect of androgen receptor directed therapy in prostate cancer patients with COVID-19. Journal Of Clinical Oncology 2022, 40: 161-161. DOI: 10.1200/jco.2022.40.6_suppl.161.
- Aapro M, Bossi P, Dasari A, Fallowfield L, Gascón P, Geller M, Jordan K, Kim J, Martin K, Porzig S. Digital Health for Optimal Supportive Care in Oncology: Benefits, Limits, and Future Perspectives. Kompass Nutrition & Dietetics 2021, 1: 72-90. DOI: 10.1159/000519151.
- Kim J, Radke M, Hafez N, Soliman H, Fu S, Kato S, Lara P, Vaishampayan U, Razak A, Cardin D, Munster P, Eder J, Shyr Y, Ivy S, LoRusso P, Swisher E. Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study. Journal Of Clinical Oncology 2021, 39: 8563-8563. DOI: 10.1200/jco.2021.39.15_suppl.8563.
- Hu Y, Narayan A, Wolfe J, Vu D, Thi T, Kantak C, Ivy S, Eder J, LoRusso P, Kim J, Patel A. Dynamics of circulating tumor DNA in patients with advanced solid tumors treated with cediranib and olaparib. Journal Of Clinical Oncology 2021, 39: 3035-3035. DOI: 10.1200/jco.2021.39.15_suppl.3035.
- Kim J, Cardin DB, Vaishampayan UN, Kato S, Grossman SR, Glazer P, Shyr Y, Ivy SP, LoRusso P. Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation. The Oncologist 2021, 26: e1104-e1109. PMID: 33742489, PMCID: PMC8265343, DOI: 10.1002/onco.13758.
- McKay R, Radke M, Shyr Y, Zhao S, Taplin M, Davis N, Monk P, Appleman L, Lara P, Vaishampayan U, Zhang J, Paul A, Bubley G, Huang Y, Shapiro G, LoRusso P, Ivy S, Petrylak D, Swisher E, Kim J. Biomarker analysis from a randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2021, 39: 7-7. DOI: 10.1200/jco.2021.39.6_suppl.7.
- Petrylak DP, Loriot Y, Shaffer DR, Braiteh F, Powderly J, Harshman LC, Conkling P, Delord JP, Gordon M, Kim JW, Sarkar I, Yuen K, Kadel EE, Mariathasan S, O'Hear C, Narayanan S, Fassò M, Carroll S, Powles T. Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyAtezolizumab in Castration-Resistant Prostate Cancer. Clinical Cancer Research 2021, 27: 3360-3369. PMID: 33568344, DOI: 10.1158/1078-0432.ccr-20-1981.
- Madan RA, Karzai FH, Harthy M, Petrylak DP, Kim JW, Arlen PM, Rosner I, Theoret MR, Cordes L, Bilusic M, Peer CJ, Dawson NA, Couvillon A, Hankin A, Williams M, Chun G, Owens H, Marte JL, Lee M, Tomita Y, Yuno A, Trepel JB, Lee S, Steinberg SM, Gulley JL, Figg WD, Dahut WL. Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer. BJU International 2020, 127: 435-444. PMID: 32969563, PMCID: PMC8265825, DOI: 10.1111/bju.15227.
- Aapro M, Bossi P, Dasari A, Fallowfield L, Gascón P, Geller M, Jordan K, Kim J, Martin K, Porzig S. Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. Supportive Care In Cancer 2020, 28: 4589-4612. PMID: 32533435, PMCID: PMC7447627, DOI: 10.1007/s00520-020-05539-1.
- Kim J, Hafez N, Soliman H, Fu S, Kato S, Lara P, Vaishampayan U, Abdul Razak A, Cardin D, Munster P, Eder J, Swisher E, Nixon A, Patel A, Shyr Y, Ivy S, LoRusso P. Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors. Journal Of Clinical Oncology 2020, 38: 9065-9065. DOI: 10.1200/jco.2020.38.15_suppl.9065.
- Hafez N, Soliman H, Fu S, Gelmon K, Abdul Razak A, Munster P, Vaishampayan U, Kato S, Lara P, Swisher E, Nixon A, Patel A, Shyr Y, Ivy S, LoRusso P, Kim J. Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors. Journal Of Clinical Oncology 2020, 38: 1077-1077. DOI: 10.1200/jco.2020.38.15_suppl.1077.
- Kim J, McKay R, Taplin M, Davis N, Monk P, Appleman L, Lara P, Vaishampayan U, Zhang J, Paul A, Bubley G, Van Allen E, Huang Y, Zhang Z, Loda M, Shapiro G, LoRusso P, Ivy S, Petrylak D. Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2020, 38: 111-111. DOI: 10.1200/jco.2020.38.6_suppl.111.
- Somaiah N, Chawla SP, Block MS, Morris JC, Do K, Kim JW, Druta M, Sankhala KK, Hwu P, Jones RL, Gnjatic S, Kim-Schulze S, Tuballes K, Yishak M, Lu H, Yakovich A, Meulen J, Chen M, Kenney RT, Bohac C, Pollack SM. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. OncoImmunology 2020, 9: 1847846. PMID: 33312760, PMCID: PMC7714520, DOI: 10.1080/2162402x.2020.1847846.
- Somaiah N, Block MS, Kim JW, Shapiro GI, T. K, Hwu P, Eder J, Jones RL, Lu H, Meulen J, Bohac C, Chen M, Hsu FJ, Gnjatic S, Pollack SM. First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clinical Cancer Research 2019, 25: 5808-5817. PMID: 31227504, DOI: 10.1158/1078-0432.ccr-19-1025.
- Harthy M, Madan R, Karzai F, Petrylak D, Kim J, Arlen P, Theoret M, Marte J, Bilusic M, Couvillon A, Chun G, Owens H, Hankin A, Cordes L, Figg W, Gulley J, Dahut W. A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2019, 37: 173-173. DOI: 10.1200/jco.2019.37.7_suppl.173.
- Shin MS, Yim K, Moon K, Park HJ, Mohanty S, Kim JW, Montgomery RR, Shaw AC, Krishnaswamy S, Kang I. Dissecting alterations in human CD8+ T cells with aging by high-dimensional single cell mass cytometry. Clinical Immunology 2019, 200: 24-30. PMID: 30659916, PMCID: PMC6443094, DOI: 10.1016/j.clim.2019.01.005.
- Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marté J, Madan RA, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL. First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. Clinical Cancer Research 2019, 25: 99-109. PMID: 30131389, PMCID: PMC6320276, DOI: 10.1158/1078-0432.ccr-18-1512.
- Chawla S, Pollack S, Block M, Druta M, Do K, Morris J, Kim J, Bohac C, Lu H, Gnjatic S, Jones R, Hwu P, Somaiah N. 1607PD Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy. Annals Of Oncology 2018, 29: viii578. DOI: 10.1093/annonc/mdy299.006.
- Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. Journal Of Clinical Oncology 2018, 36: 2836-2844. PMID: 30110194, PMCID: PMC6161834, DOI: 10.1200/jco.2017.76.6212.
- Kim J, Shin M, Kang Y, Kang I, Petrylak D. Survival and immune analysis of radium-223 in patients with metastatic prostate cancer. Journal Of Clinical Oncology 2018, 36: e24144-e24144. DOI: 10.1200/jco.2018.36.15_suppl.e24144.
- Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW, Ding B, Kaiser C, Fassò M, O’Hear C, Vogelzang NJ. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study. JAMA Oncology 2018, 4: 537-544. PMID: 29423515, PMCID: PMC5885219, DOI: 10.1001/jamaoncol.2017.5440.
- Sharma P, Callahan M, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai R, Ott P, De Braud F, Morse M, Le D, Taylor M, Bendell J, Jäger D, Chism D, Antonia S, Aanur N, Yang L, Rosenberg J. Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study. Journal Of Clinical Oncology 2018, 36: 414-414. DOI: 10.1200/jco.2018.36.6_suppl.414.
- Kim J, Shaffer D, Massard C, Powles T, Harshman L, Braiteh F, Conkling P, Sarkar I, Kadel E, Mariathasan S, O'Hear C, Schiff C, Fasso M, Carroll S, Petrylak D. A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2018, 36: 187-187. DOI: 10.1200/jco.2018.36.6_suppl.187.
- Kim JW, Shin MS, Kang Y, Kang I, Petrylak DP. Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer. Clinical Genitourinary Cancer 2017, 16: e469-e476. PMID: 29137877, PMCID: PMC5878980, DOI: 10.1016/j.clgc.2017.10.010.
- Ascierto PA, Daniele B, Hammers H, Hirsh V, Kim J, Licitra L, Nanda R, Pignata S. Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016. Journal Of Translational Medicine 2017, 15: 205. PMID: 29020960, PMCID: PMC5637331, DOI: 10.1186/s12967-017-1309-2.
- Ott P, Le D, Kim J, Ascierto P, Sharma P, Bono P, Peltola K, Jäger D, Evans T, de Braud F, Chau I, Bendell J, Tschaika M, Harbison C, Zhao H, Calvo E, Janjigian Y. 674P Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032. Annals Of Oncology 2017, 28: v229-v230. DOI: 10.1093/annonc/mdx369.058.
- Janjigian Y, Jäger D, Ott A, Calvo E, Kim J, Ascierto P, Sharma P, Peltola K, Adams J, de Braud F, Chao I, Tschaika M, Harbison C, Cai W, Bendell J, Le D. Nivolumab (N)± Ipilimumab (I) bei Patienten mit fortgeschrittenem/metastasiertem chemotherapie-refraktärem (CTx-R) Magenkrebs (G), Speiseröhrenkrebs (E) oder Adenokarzinom des ösophagogastralen Übergangs (GEJ): CheckMate 032 Studie. Zeitschrift Für Gastroenterologie 2017, 55: e57-e299. DOI: 10.1055/s-0037-1604772.
- Janjigian Y, Ott P, Calvo E, Kim J, Ascierto P, Sharma P, Peltola K, Jaeger D, Evans T, De Braud F, Chau I, Tschaika M, Harbison C, Cai W, Bendell J, Le D. Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. Journal Of Clinical Oncology 2017, 35: 4014-4014. DOI: 10.1200/jco.2017.35.15_suppl.4014.
- Pollack S, Lu H, Somaiah N, Chawla S, Morris J, Do K, Kim J, Block M, Vignali M, Rytlewski J, Yusko E, Hsu F, Bohac G, Gnjatic S, Ter Meulen J. Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients. Journal Of Clinical Oncology 2017, 35: 3090-3090. DOI: 10.1200/jco.2017.35.15_suppl.3090.
- Somaiah N, Chawla S, Block M, Morris J, Do K, Kim J, Druta M, Sankhala K, Hwu P, Gnjatic S, Lu H, Kenney R, Bohac G, Pollack S. Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS). Journal Of Clinical Oncology 2017, 35: 11006-11006. DOI: 10.1200/jco.2017.35.15_suppl.11006.
- Petrylak D, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales R, Burris H, Kim J, Ding B, Chang D, Fasso M, O'Hear C, Vogelzang N. Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study. Journal Of Clinical Oncology 2017, 35: 290-290. DOI: 10.1200/jco.2017.35.6_suppl.290.
- Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, Le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. The Lancet Oncology 2016, 17: 1590-1598. PMID: 27733243, PMCID: PMC5648054, DOI: 10.1016/s1470-2045(16)30496-x.
- Rosenberg J, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai R, Ott P, de Braud F, Morse M, Le D, Jaeger D, Chan E, Harbison C, Lin C, Tschaika M, Azrilevich A, Sharma P. 784P Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study. Annals Of Oncology 2016, 27: vi271. DOI: 10.1093/annonc/mdw373.12.
- Sharma P, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai R, Ott P, De Braud F, Morse M, Le D, Jaeger D, Chan E, Harbison C, Lin C, Tschaika M, Azrilevich A, Rosenberg J. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. Journal Of Clinical Oncology 2016, 34: 4501-4501. DOI: 10.1200/jco.2016.34.15_suppl.4501.
- Janjigian Y, Bendell J, Calvo E, Kim J, Ascierto P, Sharma P, Ott P, Bono P, Jaeger D, Evans T, De Braud F, Chau I, Tschaika M, Harbison C, Lin C, Le D. CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). Journal Of Clinical Oncology 2016, 34: 4010-4010. DOI: 10.1200/jco.2016.34.15_suppl.4010.
- Somaiah N, Block M, Kim J, Shapiro G, Do K, Hwu P, Eder J, Jones R, Gnjatic S, Lu H, Ter Meulen J, Hsu F, Pollack S. Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1. Journal Of Clinical Oncology 2016, 34: 3093-3093. DOI: 10.1200/jco.2016.34.15_suppl.3093.
- Le D, Bendell J, Calvo E, Kim J, Ascierto P, Sharma P, Ott P, Bono P, Jaeger D, Evans T, De Braud F, Chau I, Christensen O, Harbison C, Lin C, Janjigian Y. Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study. Journal Of Clinical Oncology 2016, 34: 6-6. DOI: 10.1200/jco.2016.34.4_suppl.6.
- Apolo AB, Lindenberg L, Shih JH, Mena E, Kim JW, Park JC, Alikhani A, McKinney YY, Weaver J, Turkbey B, Parnes HL, Wood LV, Madan RA, Gulley JL, Dahut WL, Kurdziel KA, Choyke PL. Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. Journal Of Nuclear Medicine 2016, 57: 886-892. PMID: 26795292, PMCID: PMC6599519, DOI: 10.2967/jnumed.115.166512.
- Kim J, Kang Y, Shin M, Deshpande H, Hurwitz M, Roberts J, Cardinale J, Narayana A, Kang I, Petrylak D. Changes in T cell immunity in patients with metastatic castration resistant prostate treated with Radium-223 treatment. Journal Of Clinical Oncology 2016, 34: 295-295. DOI: 10.1200/jco.2016.34.2_suppl.295.
- Powles T, Nickles D, Van Allen E, Chappey C, Zou W, Kowanetz M, Kadel E, Denker M, Boyd Z, Vogelzang N, Kim J, Bellmunt J, Loriot Y, Drake C, O'Hear C, Fasso M, Hegde P, Mariathasan S. Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). Journal For ImmunoTherapy Of Cancer 2015, 3: p83. PMCID: PMC4645499, DOI: 10.1186/2051-1426-3-s2-p83.
- Petrylak D, Powles T, Bellmunt J, Braiteh F, Loriot Y, Cruz Zambrano C, Burris H, Kim J, Teng S, Bruey J, Hegde P, Abidoye O, Vogelzang N. A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). Journal Of Clinical Oncology 2015, 33: 4501-4501. DOI: 10.1200/jco.2015.33.15_suppl.4501.
- Somaiah N, Block M, Kim J, Shapiro G, Hwu P, Eder J, Jones R, Gnjatic S, Lu H, Hsu F, Pollack S. Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1. Journal Of Clinical Oncology 2015, 33: 3021-3021. DOI: 10.1200/jco.2015.33.15_suppl.3021.
- Kim JW, Tomita Y, Trepel J, Apolo AB. Emerging immunotherapies for bladder cancer. Current Opinion In Oncology 2015, 27: 191-200. PMID: 25811346, PMCID: PMC7709951, DOI: 10.1097/cco.0000000000000177.
- Kim JW, Bilusic M, Plimack ER. Mechanisms of immunotherapy resistance in mCRPC: identifying the enemy on the visceral metastatic battlefield. Oncology 2014, 28: 986-90. PMID: 25403631.
- Kim JW, Eder JP. Prospects for targeting PD-1 and PD-L1 in various tumor types. Oncology 2014, 28 Suppl 3: 15-28. PMID: 25387682.
- Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kelly K, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046). Urologic Oncology Seminars And Original Investigations 2014, 32: 637-644. PMID: 24840869, PMCID: PMC6771274, DOI: 10.1016/j.urolonc.2013.12.012.
- Singh N, Kim J, Heery C, Dahut W, Couvillon A, Rauckhorst M, McMahon S, Schlom J, Fojo T, Arlen P, Gulley J, Madan R. A randomized phase II clinical trial of enzalutamide in combination with the therapeutic cancer vaccine, PSA tricom, in metastatic, castration resistant prostate cancer. Journal Of Clinical Oncology 2013, 31: tps5104-tps5104. DOI: 10.1200/jco.2013.31.15_suppl.tps5104.
- Kim J, Marte J, Singh N, Heery C, Madan R, Pazdur M, McMahon S, Rauckhorst M, Schlom J, Kantoff P, Gulley J. Safety profile of recombinant poxviral TRICOM vaccines. Journal Of Clinical Oncology 2013, 31: e16036-e16036. DOI: 10.1200/jco.2013.31.15_suppl.e16036.
- Kim J, Marte J, Bilusic M, Singh N, Heery C, Madan R, Pazdur M, McMahon S, Rauckhorst M, Schlom J, Gulley J. Safety profile of poxviral vaccines: NCI experience. Journal Of Clinical Oncology 2013, 31: 85-85. DOI: 10.1200/jco.2013.31.6_suppl.85.
- Heery C, Madan R, Bilusic M, Kim J, Singh N, Rauckhorst M, Steinberg S, Dahut W, Chen C, DiPaola R, Stein M, Panicali D, Hodge J, Schlom J, Gulley J. A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. Journal Of Clinical Oncology 2013, 31: 102-102. DOI: 10.1200/jco.2013.31.6_suppl.102.
- Kim JW, Bilusic M, Heery CJ, Madan RA. Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response. Cancers 2012, 4: 1229-1246. PMID: 24213505, PMCID: PMC3712729, DOI: 10.3390/cancers4041229.
- Kim JW, Marshall JL. Improving harmonious precision. Oncology 2012, 26: 949, 954. PMID: 23176007.
- Kim JW. ASCO beyond McCormick: perseverance, collaboration, mentorship. Community Oncology 2012, 9: 265. PMID: 23028260, PMCID: PMC3460519, DOI: 10.1016/j.cmonc.2012.07.004.
- Singh N, Bilusic M, Kim J, Heery C, Falk M, Wood B, Pinto P, Dahut W, Kaushal A, Couvillon A, Rauckhorst M, Choyke P, Turkbey I, Trepel J, Tsang K, Schlom J, Gulley J, Madan R. Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer. Journal Of Clinical Oncology 2012, 30: tps4701-tps4701. DOI: 10.1200/jco.2012.30.15_suppl.tps4701.
- Kim J, Heery C, Bilusic M, Singh N, Madan R, Sabzevari H, Schlom J, Gulley J. First-in-human phase I trial of NHS-IL12 in advanced solid tumors. Journal Of Clinical Oncology 2012, 30: tps2617-tps2617. DOI: 10.1200/jco.2012.30.15_suppl.tps2617.
- Heery C, Madan R, Bilusic M, Kim J, Singh N, Rauckhorst M, Chen C, Dahut W, Stadler W, DiPaola R, Stein M, Hodge J, Schlom J, Gulley J. Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel. Journal Of Clinical Oncology 2012, 30: 2526-2526. DOI: 10.1200/jco.2012.30.15_suppl.2526.
- Kim J, Lindenberg M, Dahut W, Gulley J, Madan R, Wood L, McKinney Y, Choyke P, Kurdziel K, Apolo A. A pilot study on the clinical value of 18 F-sodium fluoride PET/CT in advanced prostate cancer. Journal Of Clinical Oncology 2012, 30: 10589-10589. DOI: 10.1200/jco.2012.30.15_suppl.10589.
- Kim JW, Gulley JL. Poxviral vectors for cancer immunotherapy. Expert Opinion On Biological Therapy 2012, 12: 463-478. PMID: 22413824, PMCID: PMC3482162, DOI: 10.1517/14712598.2012.668516.
- Kim JW, Madan RA, Gulley JL. Initial PSA Oscillations Precede Prolonged Stable Disease in a Patient Treated With a Therapeutic Cancer Vaccine. Clinical Genitourinary Cancer 2011, 10: 43-46. PMID: 22019260, PMCID: PMC3279569, DOI: 10.1016/j.clgc.2011.09.003.
- Kim JW, Amin AR, Shin DM. Chemoprevention of Head and Neck Cancer with Green Tea Polyphenols. Cancer Prevention Research 2010, 3: 900-909. PMID: 20663981, PMCID: PMC2917478, DOI: 10.1158/1940-6207.capr-09-0131.
- Hicks AM, Riedlinger G, Willingham MC, Alexander-Miller MA, Von Kap-Herr C, Pettenati MJ, Sanders AM, Weir HM, Du W, Kim J, Simpson AJ, Old LJ, Cui Z. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proceedings Of The National Academy Of Sciences Of The United States Of America 2006, 103: 7753-7758. PMID: 16682640, PMCID: PMC1458507, DOI: 10.1073/pnas.0602382103.
- Limentani SA, Asher A, Heafner M, Kim JW, Fraser R. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. Journal Of Neuro-Oncology 2005, 72: 241-244. PMID: 15937647, DOI: 10.1007/s11060-004-2339-1.
Locations
1
Yale Cancer Center - Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 8
New Haven, CT 06511
1 of 2
- Yale Cancer Center - Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 8New Haven, CT 06511
- Smilow Cancer Hospital Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 2North Haven, CT 06473
Biography
Joseph Kim, MD, is an associate professor at Yale School of Medicine and the director of Prostate Cancer Research at Yale Cancer Center. A Yale Medicine oncology specialist, he delivers compassionate, patient-centered, and evidence-based care for patients with genitourinary cancer including prostate cancer, bladder cancer, testicular cancer, and penile cancer. Dr. Kim offers advanced treatments, such as cancer immunotherapy and oral inhibitors based on genomic biomarkers for prostate cancer and bladder cancer.
His research interests encompass developing novel anti-cancer therapies for genitourinary cancers through early phase clinical trials. Dr. Kim's research also explores changes in tumor DNA during treatment for patients with advanced prostate cancer.
Dr. Kim's impactful research has been recognized through several awards, including the Young Investigator Award and the Merit Award from the Conque Cancer Foundation with the American Society of Clinical Oncology, as well as the Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute.
Titles
- Associate Professor of Internal Medicine (Medical Oncology)
- Director, Prostate Cancer Research
- Lecture Coordinator in Hematology/Oncology, Yale Affiliated Hospital Program
Education & Training
- FellowNational Institutes of Health (2013)
- ResidentEmory University School of Medicine (2010)
- MDWake Forest University School of Medicine (2007)
- BACovenant College, Biology, Pre-Medicine (2001)
Languages Spoken
- English
- 한국어 (Korean)
Additional Information
Honors & Recognitions
- Cancer Clinical Investigator Team Leadership Award (CCITLA): NCI (2021)
- Young Investigator Award: Conquer Cancer Foundation, American Society of Clinical Oncology (2013)
- Merit Award: Conqer Cancer Foundation, American Society of Clinical Oncology (2013)
Professional Service
- ASCO-SEP (2021 - Present): Editor
- Frontiers Oncology (2019 - Present): Reviewer
- Current Oncology Reports (2015 - Present): Editor
- American Association for Cancer Research (2014 - Present): Member
- Society of Immunotherapy of Cancer (2013 - Present): Member
- American Society of Clinical Oncology (2010 - Present): Member
Publications
- Ünlü S, Shin J, Par-Young J, Simonov M, Vinetz J, Petrylak D, Kang I, Kim J. Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients. Cancer Investigation 2022, 41: 77-83. PMID: 36373994, DOI: 10.1080/07357907.2022.2139839.
- Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. Journal Of Clinical Oncology 2022, 41: 871-880. PMID: 36256912, PMCID: PMC9901975, DOI: 10.1200/jco.21.02947.
- Unlu S, Kim JW. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer. Current Oncology Reports 2022, 24: 1619-1631. PMID: 35931885, DOI: 10.1007/s11912-022-01305-0.
- Unlu S, Shin J, Par-Young J, Vinetz J, Petrylak D, Kang I, Kim J. Effect of androgen receptor directed therapy in prostate cancer patients with COVID-19. Journal Of Clinical Oncology 2022, 40: 161-161. DOI: 10.1200/jco.2022.40.6_suppl.161.
- Aapro M, Bossi P, Dasari A, Fallowfield L, Gascón P, Geller M, Jordan K, Kim J, Martin K, Porzig S. Digital Health for Optimal Supportive Care in Oncology: Benefits, Limits, and Future Perspectives. Kompass Nutrition & Dietetics 2021, 1: 72-90. DOI: 10.1159/000519151.
- Kim J, Radke M, Hafez N, Soliman H, Fu S, Kato S, Lara P, Vaishampayan U, Razak A, Cardin D, Munster P, Eder J, Shyr Y, Ivy S, LoRusso P, Swisher E. Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study. Journal Of Clinical Oncology 2021, 39: 8563-8563. DOI: 10.1200/jco.2021.39.15_suppl.8563.
- Hu Y, Narayan A, Wolfe J, Vu D, Thi T, Kantak C, Ivy S, Eder J, LoRusso P, Kim J, Patel A. Dynamics of circulating tumor DNA in patients with advanced solid tumors treated with cediranib and olaparib. Journal Of Clinical Oncology 2021, 39: 3035-3035. DOI: 10.1200/jco.2021.39.15_suppl.3035.
- Kim J, Cardin DB, Vaishampayan UN, Kato S, Grossman SR, Glazer P, Shyr Y, Ivy SP, LoRusso P. Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation. The Oncologist 2021, 26: e1104-e1109. PMID: 33742489, PMCID: PMC8265343, DOI: 10.1002/onco.13758.
- McKay R, Radke M, Shyr Y, Zhao S, Taplin M, Davis N, Monk P, Appleman L, Lara P, Vaishampayan U, Zhang J, Paul A, Bubley G, Huang Y, Shapiro G, LoRusso P, Ivy S, Petrylak D, Swisher E, Kim J. Biomarker analysis from a randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2021, 39: 7-7. DOI: 10.1200/jco.2021.39.6_suppl.7.
- Petrylak DP, Loriot Y, Shaffer DR, Braiteh F, Powderly J, Harshman LC, Conkling P, Delord JP, Gordon M, Kim JW, Sarkar I, Yuen K, Kadel EE, Mariathasan S, O'Hear C, Narayanan S, Fassò M, Carroll S, Powles T. Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyAtezolizumab in Castration-Resistant Prostate Cancer. Clinical Cancer Research 2021, 27: 3360-3369. PMID: 33568344, DOI: 10.1158/1078-0432.ccr-20-1981.
- Madan RA, Karzai FH, Harthy M, Petrylak DP, Kim JW, Arlen PM, Rosner I, Theoret MR, Cordes L, Bilusic M, Peer CJ, Dawson NA, Couvillon A, Hankin A, Williams M, Chun G, Owens H, Marte JL, Lee M, Tomita Y, Yuno A, Trepel JB, Lee S, Steinberg SM, Gulley JL, Figg WD, Dahut WL. Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer. BJU International 2020, 127: 435-444. PMID: 32969563, PMCID: PMC8265825, DOI: 10.1111/bju.15227.
- Aapro M, Bossi P, Dasari A, Fallowfield L, Gascón P, Geller M, Jordan K, Kim J, Martin K, Porzig S. Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. Supportive Care In Cancer 2020, 28: 4589-4612. PMID: 32533435, PMCID: PMC7447627, DOI: 10.1007/s00520-020-05539-1.
- Kim J, Hafez N, Soliman H, Fu S, Kato S, Lara P, Vaishampayan U, Abdul Razak A, Cardin D, Munster P, Eder J, Swisher E, Nixon A, Patel A, Shyr Y, Ivy S, LoRusso P. Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors. Journal Of Clinical Oncology 2020, 38: 9065-9065. DOI: 10.1200/jco.2020.38.15_suppl.9065.
- Hafez N, Soliman H, Fu S, Gelmon K, Abdul Razak A, Munster P, Vaishampayan U, Kato S, Lara P, Swisher E, Nixon A, Patel A, Shyr Y, Ivy S, LoRusso P, Kim J. Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors. Journal Of Clinical Oncology 2020, 38: 1077-1077. DOI: 10.1200/jco.2020.38.15_suppl.1077.
- Kim J, McKay R, Taplin M, Davis N, Monk P, Appleman L, Lara P, Vaishampayan U, Zhang J, Paul A, Bubley G, Van Allen E, Huang Y, Zhang Z, Loda M, Shapiro G, LoRusso P, Ivy S, Petrylak D. Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2020, 38: 111-111. DOI: 10.1200/jco.2020.38.6_suppl.111.
- Somaiah N, Chawla SP, Block MS, Morris JC, Do K, Kim JW, Druta M, Sankhala KK, Hwu P, Jones RL, Gnjatic S, Kim-Schulze S, Tuballes K, Yishak M, Lu H, Yakovich A, Meulen J, Chen M, Kenney RT, Bohac C, Pollack SM. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. OncoImmunology 2020, 9: 1847846. PMID: 33312760, PMCID: PMC7714520, DOI: 10.1080/2162402x.2020.1847846.
- Somaiah N, Block MS, Kim JW, Shapiro GI, T. K, Hwu P, Eder J, Jones RL, Lu H, Meulen J, Bohac C, Chen M, Hsu FJ, Gnjatic S, Pollack SM. First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clinical Cancer Research 2019, 25: 5808-5817. PMID: 31227504, DOI: 10.1158/1078-0432.ccr-19-1025.
- Harthy M, Madan R, Karzai F, Petrylak D, Kim J, Arlen P, Theoret M, Marte J, Bilusic M, Couvillon A, Chun G, Owens H, Hankin A, Cordes L, Figg W, Gulley J, Dahut W. A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2019, 37: 173-173. DOI: 10.1200/jco.2019.37.7_suppl.173.
- Shin MS, Yim K, Moon K, Park HJ, Mohanty S, Kim JW, Montgomery RR, Shaw AC, Krishnaswamy S, Kang I. Dissecting alterations in human CD8+ T cells with aging by high-dimensional single cell mass cytometry. Clinical Immunology 2019, 200: 24-30. PMID: 30659916, PMCID: PMC6443094, DOI: 10.1016/j.clim.2019.01.005.
- Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marté J, Madan RA, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL. First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. Clinical Cancer Research 2019, 25: 99-109. PMID: 30131389, PMCID: PMC6320276, DOI: 10.1158/1078-0432.ccr-18-1512.
- Chawla S, Pollack S, Block M, Druta M, Do K, Morris J, Kim J, Bohac C, Lu H, Gnjatic S, Jones R, Hwu P, Somaiah N. 1607PD Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy. Annals Of Oncology 2018, 29: viii578. DOI: 10.1093/annonc/mdy299.006.
- Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. Journal Of Clinical Oncology 2018, 36: 2836-2844. PMID: 30110194, PMCID: PMC6161834, DOI: 10.1200/jco.2017.76.6212.
- Kim J, Shin M, Kang Y, Kang I, Petrylak D. Survival and immune analysis of radium-223 in patients with metastatic prostate cancer. Journal Of Clinical Oncology 2018, 36: e24144-e24144. DOI: 10.1200/jco.2018.36.15_suppl.e24144.
- Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW, Ding B, Kaiser C, Fassò M, O’Hear C, Vogelzang NJ. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study. JAMA Oncology 2018, 4: 537-544. PMID: 29423515, PMCID: PMC5885219, DOI: 10.1001/jamaoncol.2017.5440.
- Sharma P, Callahan M, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai R, Ott P, De Braud F, Morse M, Le D, Taylor M, Bendell J, Jäger D, Chism D, Antonia S, Aanur N, Yang L, Rosenberg J. Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study. Journal Of Clinical Oncology 2018, 36: 414-414. DOI: 10.1200/jco.2018.36.6_suppl.414.
- Kim J, Shaffer D, Massard C, Powles T, Harshman L, Braiteh F, Conkling P, Sarkar I, Kadel E, Mariathasan S, O'Hear C, Schiff C, Fasso M, Carroll S, Petrylak D. A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2018, 36: 187-187. DOI: 10.1200/jco.2018.36.6_suppl.187.
- Kim JW, Shin MS, Kang Y, Kang I, Petrylak DP. Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer. Clinical Genitourinary Cancer 2017, 16: e469-e476. PMID: 29137877, PMCID: PMC5878980, DOI: 10.1016/j.clgc.2017.10.010.
- Ascierto PA, Daniele B, Hammers H, Hirsh V, Kim J, Licitra L, Nanda R, Pignata S. Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016. Journal Of Translational Medicine 2017, 15: 205. PMID: 29020960, PMCID: PMC5637331, DOI: 10.1186/s12967-017-1309-2.
- Ott P, Le D, Kim J, Ascierto P, Sharma P, Bono P, Peltola K, Jäger D, Evans T, de Braud F, Chau I, Bendell J, Tschaika M, Harbison C, Zhao H, Calvo E, Janjigian Y. 674P Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032. Annals Of Oncology 2017, 28: v229-v230. DOI: 10.1093/annonc/mdx369.058.
- Janjigian Y, Jäger D, Ott A, Calvo E, Kim J, Ascierto P, Sharma P, Peltola K, Adams J, de Braud F, Chao I, Tschaika M, Harbison C, Cai W, Bendell J, Le D. Nivolumab (N)± Ipilimumab (I) bei Patienten mit fortgeschrittenem/metastasiertem chemotherapie-refraktärem (CTx-R) Magenkrebs (G), Speiseröhrenkrebs (E) oder Adenokarzinom des ösophagogastralen Übergangs (GEJ): CheckMate 032 Studie. Zeitschrift Für Gastroenterologie 2017, 55: e57-e299. DOI: 10.1055/s-0037-1604772.
- Janjigian Y, Ott P, Calvo E, Kim J, Ascierto P, Sharma P, Peltola K, Jaeger D, Evans T, De Braud F, Chau I, Tschaika M, Harbison C, Cai W, Bendell J, Le D. Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. Journal Of Clinical Oncology 2017, 35: 4014-4014. DOI: 10.1200/jco.2017.35.15_suppl.4014.
- Pollack S, Lu H, Somaiah N, Chawla S, Morris J, Do K, Kim J, Block M, Vignali M, Rytlewski J, Yusko E, Hsu F, Bohac G, Gnjatic S, Ter Meulen J. Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients. Journal Of Clinical Oncology 2017, 35: 3090-3090. DOI: 10.1200/jco.2017.35.15_suppl.3090.
- Somaiah N, Chawla S, Block M, Morris J, Do K, Kim J, Druta M, Sankhala K, Hwu P, Gnjatic S, Lu H, Kenney R, Bohac G, Pollack S. Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS). Journal Of Clinical Oncology 2017, 35: 11006-11006. DOI: 10.1200/jco.2017.35.15_suppl.11006.
- Petrylak D, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales R, Burris H, Kim J, Ding B, Chang D, Fasso M, O'Hear C, Vogelzang N. Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study. Journal Of Clinical Oncology 2017, 35: 290-290. DOI: 10.1200/jco.2017.35.6_suppl.290.
- Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, Le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. The Lancet Oncology 2016, 17: 1590-1598. PMID: 27733243, PMCID: PMC5648054, DOI: 10.1016/s1470-2045(16)30496-x.
- Rosenberg J, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai R, Ott P, de Braud F, Morse M, Le D, Jaeger D, Chan E, Harbison C, Lin C, Tschaika M, Azrilevich A, Sharma P. 784P Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study. Annals Of Oncology 2016, 27: vi271. DOI: 10.1093/annonc/mdw373.12.
- Sharma P, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai R, Ott P, De Braud F, Morse M, Le D, Jaeger D, Chan E, Harbison C, Lin C, Tschaika M, Azrilevich A, Rosenberg J. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. Journal Of Clinical Oncology 2016, 34: 4501-4501. DOI: 10.1200/jco.2016.34.15_suppl.4501.
- Janjigian Y, Bendell J, Calvo E, Kim J, Ascierto P, Sharma P, Ott P, Bono P, Jaeger D, Evans T, De Braud F, Chau I, Tschaika M, Harbison C, Lin C, Le D. CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). Journal Of Clinical Oncology 2016, 34: 4010-4010. DOI: 10.1200/jco.2016.34.15_suppl.4010.
- Somaiah N, Block M, Kim J, Shapiro G, Do K, Hwu P, Eder J, Jones R, Gnjatic S, Lu H, Ter Meulen J, Hsu F, Pollack S. Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1. Journal Of Clinical Oncology 2016, 34: 3093-3093. DOI: 10.1200/jco.2016.34.15_suppl.3093.
- Le D, Bendell J, Calvo E, Kim J, Ascierto P, Sharma P, Ott P, Bono P, Jaeger D, Evans T, De Braud F, Chau I, Christensen O, Harbison C, Lin C, Janjigian Y. Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study. Journal Of Clinical Oncology 2016, 34: 6-6. DOI: 10.1200/jco.2016.34.4_suppl.6.
- Apolo AB, Lindenberg L, Shih JH, Mena E, Kim JW, Park JC, Alikhani A, McKinney YY, Weaver J, Turkbey B, Parnes HL, Wood LV, Madan RA, Gulley JL, Dahut WL, Kurdziel KA, Choyke PL. Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. Journal Of Nuclear Medicine 2016, 57: 886-892. PMID: 26795292, PMCID: PMC6599519, DOI: 10.2967/jnumed.115.166512.
- Kim J, Kang Y, Shin M, Deshpande H, Hurwitz M, Roberts J, Cardinale J, Narayana A, Kang I, Petrylak D. Changes in T cell immunity in patients with metastatic castration resistant prostate treated with Radium-223 treatment. Journal Of Clinical Oncology 2016, 34: 295-295. DOI: 10.1200/jco.2016.34.2_suppl.295.
- Powles T, Nickles D, Van Allen E, Chappey C, Zou W, Kowanetz M, Kadel E, Denker M, Boyd Z, Vogelzang N, Kim J, Bellmunt J, Loriot Y, Drake C, O'Hear C, Fasso M, Hegde P, Mariathasan S. Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). Journal For ImmunoTherapy Of Cancer 2015, 3: p83. PMCID: PMC4645499, DOI: 10.1186/2051-1426-3-s2-p83.
- Petrylak D, Powles T, Bellmunt J, Braiteh F, Loriot Y, Cruz Zambrano C, Burris H, Kim J, Teng S, Bruey J, Hegde P, Abidoye O, Vogelzang N. A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). Journal Of Clinical Oncology 2015, 33: 4501-4501. DOI: 10.1200/jco.2015.33.15_suppl.4501.
- Somaiah N, Block M, Kim J, Shapiro G, Hwu P, Eder J, Jones R, Gnjatic S, Lu H, Hsu F, Pollack S. Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1. Journal Of Clinical Oncology 2015, 33: 3021-3021. DOI: 10.1200/jco.2015.33.15_suppl.3021.
- Kim JW, Tomita Y, Trepel J, Apolo AB. Emerging immunotherapies for bladder cancer. Current Opinion In Oncology 2015, 27: 191-200. PMID: 25811346, PMCID: PMC7709951, DOI: 10.1097/cco.0000000000000177.
- Kim JW, Bilusic M, Plimack ER. Mechanisms of immunotherapy resistance in mCRPC: identifying the enemy on the visceral metastatic battlefield. Oncology 2014, 28: 986-90. PMID: 25403631.
- Kim JW, Eder JP. Prospects for targeting PD-1 and PD-L1 in various tumor types. Oncology 2014, 28 Suppl 3: 15-28. PMID: 25387682.
- Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kelly K, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046). Urologic Oncology Seminars And Original Investigations 2014, 32: 637-644. PMID: 24840869, PMCID: PMC6771274, DOI: 10.1016/j.urolonc.2013.12.012.
- Singh N, Kim J, Heery C, Dahut W, Couvillon A, Rauckhorst M, McMahon S, Schlom J, Fojo T, Arlen P, Gulley J, Madan R. A randomized phase II clinical trial of enzalutamide in combination with the therapeutic cancer vaccine, PSA tricom, in metastatic, castration resistant prostate cancer. Journal Of Clinical Oncology 2013, 31: tps5104-tps5104. DOI: 10.1200/jco.2013.31.15_suppl.tps5104.
- Kim J, Marte J, Singh N, Heery C, Madan R, Pazdur M, McMahon S, Rauckhorst M, Schlom J, Kantoff P, Gulley J. Safety profile of recombinant poxviral TRICOM vaccines. Journal Of Clinical Oncology 2013, 31: e16036-e16036. DOI: 10.1200/jco.2013.31.15_suppl.e16036.
- Kim J, Marte J, Bilusic M, Singh N, Heery C, Madan R, Pazdur M, McMahon S, Rauckhorst M, Schlom J, Gulley J. Safety profile of poxviral vaccines: NCI experience. Journal Of Clinical Oncology 2013, 31: 85-85. DOI: 10.1200/jco.2013.31.6_suppl.85.
- Heery C, Madan R, Bilusic M, Kim J, Singh N, Rauckhorst M, Steinberg S, Dahut W, Chen C, DiPaola R, Stein M, Panicali D, Hodge J, Schlom J, Gulley J. A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. Journal Of Clinical Oncology 2013, 31: 102-102. DOI: 10.1200/jco.2013.31.6_suppl.102.
- Kim JW, Bilusic M, Heery CJ, Madan RA. Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response. Cancers 2012, 4: 1229-1246. PMID: 24213505, PMCID: PMC3712729, DOI: 10.3390/cancers4041229.
- Kim JW, Marshall JL. Improving harmonious precision. Oncology 2012, 26: 949, 954. PMID: 23176007.
- Kim JW. ASCO beyond McCormick: perseverance, collaboration, mentorship. Community Oncology 2012, 9: 265. PMID: 23028260, PMCID: PMC3460519, DOI: 10.1016/j.cmonc.2012.07.004.
- Singh N, Bilusic M, Kim J, Heery C, Falk M, Wood B, Pinto P, Dahut W, Kaushal A, Couvillon A, Rauckhorst M, Choyke P, Turkbey I, Trepel J, Tsang K, Schlom J, Gulley J, Madan R. Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer. Journal Of Clinical Oncology 2012, 30: tps4701-tps4701. DOI: 10.1200/jco.2012.30.15_suppl.tps4701.
- Kim J, Heery C, Bilusic M, Singh N, Madan R, Sabzevari H, Schlom J, Gulley J. First-in-human phase I trial of NHS-IL12 in advanced solid tumors. Journal Of Clinical Oncology 2012, 30: tps2617-tps2617. DOI: 10.1200/jco.2012.30.15_suppl.tps2617.
- Heery C, Madan R, Bilusic M, Kim J, Singh N, Rauckhorst M, Chen C, Dahut W, Stadler W, DiPaola R, Stein M, Hodge J, Schlom J, Gulley J. Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel. Journal Of Clinical Oncology 2012, 30: 2526-2526. DOI: 10.1200/jco.2012.30.15_suppl.2526.
- Kim J, Lindenberg M, Dahut W, Gulley J, Madan R, Wood L, McKinney Y, Choyke P, Kurdziel K, Apolo A. A pilot study on the clinical value of 18 F-sodium fluoride PET/CT in advanced prostate cancer. Journal Of Clinical Oncology 2012, 30: 10589-10589. DOI: 10.1200/jco.2012.30.15_suppl.10589.
- Kim JW, Gulley JL. Poxviral vectors for cancer immunotherapy. Expert Opinion On Biological Therapy 2012, 12: 463-478. PMID: 22413824, PMCID: PMC3482162, DOI: 10.1517/14712598.2012.668516.
- Kim JW, Madan RA, Gulley JL. Initial PSA Oscillations Precede Prolonged Stable Disease in a Patient Treated With a Therapeutic Cancer Vaccine. Clinical Genitourinary Cancer 2011, 10: 43-46. PMID: 22019260, PMCID: PMC3279569, DOI: 10.1016/j.clgc.2011.09.003.
- Kim JW, Amin AR, Shin DM. Chemoprevention of Head and Neck Cancer with Green Tea Polyphenols. Cancer Prevention Research 2010, 3: 900-909. PMID: 20663981, PMCID: PMC2917478, DOI: 10.1158/1940-6207.capr-09-0131.
- Hicks AM, Riedlinger G, Willingham MC, Alexander-Miller MA, Von Kap-Herr C, Pettenati MJ, Sanders AM, Weir HM, Du W, Kim J, Simpson AJ, Old LJ, Cui Z. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proceedings Of The National Academy Of Sciences Of The United States Of America 2006, 103: 7753-7758. PMID: 16682640, PMCID: PMC1458507, DOI: 10.1073/pnas.0602382103.
- Limentani SA, Asher A, Heafner M, Kim JW, Fraser R. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. Journal Of Neuro-Oncology 2005, 72: 241-244. PMID: 15937647, DOI: 10.1007/s11060-004-2339-1.
Locations
1
Yale Cancer Center - Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 8
New Haven, CT 06511
1 of 2
- Yale Cancer Center - Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 8New Haven, CT 06511
- Smilow Cancer Hospital Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 2North Haven, CT 06473
1
Yale Cancer Center - Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 8
New Haven, CT 06511
1 of 2
- Yale Cancer Center - Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 8New Haven, CT 06511
- Smilow Cancer Hospital Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 2North Haven, CT 06473